0001209191-21-015483.txt : 20210301 0001209191-21-015483.hdr.sgml : 20210301 20210301201055 ACCESSION NUMBER: 0001209191-21-015483 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210225 FILED AS OF DATE: 20210301 DATE AS OF CHANGE: 20210301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DEMAREE JOHN CENTRAL INDEX KEY: 0001744959 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36167 FILM NUMBER: 21700668 MAIL ADDRESS: STREET 1: 79 TW ALEXANDER DRIVE STREET 2: 4501 RESEARCH COMMONS, SUITE 100 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc. CENTRAL INDEX KEY: 0001503802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263931704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 85 WELLS AVENUE STREET 2: SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 BUSINESS PHONE: 617-658-0600 MAIL ADDRESS: STREET 1: 85 WELLS AVENUE STREET 2: SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-25 0 0001503802 Karyopharm Therapeutics Inc. KPTI 0001744959 DEMAREE JOHN C/O KARYOPHARM THERAPEUTICS INC. 85 WELLS AVENUE NEWTON MA 02459 0 1 0 0 Chief Commercial Officer Common Stock 2021-02-25 4 A 0 15849 0.00 A 23995 D Stock Option (right to buy) 14.56 2021-02-25 4 A 0 43177 0.00 A 2031-02-24 Common Stock 43177 43177 D Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022. The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 15,849 newly awarded RSUs and 8,146 shares of common stock, which include 646 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on October 31, 2020. This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. /s/ Nancy Smith as Attorney-in-Fact for John Demaree 2021-03-01 EX-24 2 attachment1.htm EX-24 DOCUMENT

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

Know all by these presents, that the undersigned hereby makes, constitutes and
appoints each of Michael Mano, Michael Mason and Nancy Smith, signing singly and
each acting individually, as the undersigned's true and lawful attorney in fact
with full power and authority as hereinafter described to:
(1)	execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer and/or a director of Karyopharm Therapeutics Inc. (the "Company"),
Forms 3, 4, and 5 (including any amendments thereto) in accordance with Section
16(a) of the Securities Exchange Act of 1934 and the rules thereunder (the
"Exchange Act");
(2)	do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to prepare, complete and execute any such Form 3,
4, or 5, prepare, complete and execute any amendment or amendments thereto, and
timely deliver and file such form with the United States Securities and Exchange
Commission (the "SEC") and any stock exchange or similar authority, including
without limitation the filing of a Form ID or any other application materials to
enable the undersigned to gain or maintain access to the Electronic Data
Gathering, Analysis and Retrieval system of the SEC;
(3)	seek or obtain, as the undersigned's representative and on the undersigned's
behalf, information regarding transactions in the Company's securities from any
third party, including brokers, employee benefit plan administrators and
trustees, and the undersigned hereby authorizes any such third party to release
any such information to the herein appointed attorney in fact and approves and
ratifies any such release of information; and
(4)	take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney in fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney in fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney in fact may approve in such
attorney in fact's discretion.
The undersigned hereby grants to each such attorney in fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney in fact, or such attorney
in fact's substitute or substitutes, shall lawfully do or cause to be done by
virtue of this power of attorney and the rights and powers herein granted.  The
undersigned acknowledges that the foregoing attorneys in fact, in serving in
such capacity at the request of the undersigned, are not assuming nor relieving,
nor is the Company assuming nor relieving, any of the undersigned's
responsibilities to comply with Section 16 of the Exchange Act.  The undersigned
acknowledges that neither the Company nor the foregoing attorneys in fact assume
(i) any liability for the undersigned's responsibility to comply with the
requirement of the Exchange Act, (ii) any liability of the undersigned for any
failure to comply with such requirements, or (iii) any obligation or liability
of the undersigned for profit disgorgement under Section 16(b) of the Exchange
Act.

This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with the SEC with
respect to the undersigned's holdings of and transactions in securities issued
by the Company, unless earlier revoked by the undersigned in a signed writing
delivered to the foregoing attorneys in fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 1st day of March, 2021.
/s/ John Demaree
---------------------------------
John Demaree